Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-FAP-VG11 in Advanced Solid Tumours
NCT07808177Phase 1Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-FAP-VG11 in solid tumor, sponsored by Shandong Cancer Hospital. Primary endpoints: Dose-Limiting Toxicities up to 2 years, Maximum Tolerated Dose up to 2 years and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
177Lu-FAP-VG11
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07808177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07808177.